Lyell Immunopharma Inc. held its annual meeting of stockholders on May 15, 2025. Stockholders approved the election of Catherine Friedman as a Class I director. The appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified. A proposal to effect a reverse stock split of common stock at a ratio between 1-for-10 and 1-for-25, at the discretion of the Board of Directors, was also approved.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.